These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

964 related items for PubMed ID: 20637957

  • 1. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 2. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators.
    N Engl J Med; 2006 Nov 16; 355(20):2099-112. PubMed ID: 17105757
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL, Stalker D, Keirns J.
    Clin Ther; 2009 Jul 16; 31(7):1542-50. PubMed ID: 19695403
    [Abstract] [Full Text] [Related]

  • 4. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Jul 16; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 5. Hyponatremia, heart failure, and the role of tolvaptan.
    O'Connell JB, Alemayehu A.
    Postgrad Med; 2012 Mar 16; 124(2):29-39. PubMed ID: 22437213
    [Abstract] [Full Text] [Related]

  • 6. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
    Patel GP, Balk RA.
    Clin Ther; 2007 Feb 16; 29(2):211-29. PubMed ID: 17472815
    [Abstract] [Full Text] [Related]

  • 7. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH.
    J Hepatol; 2012 Mar 16; 56(3):571-8. PubMed ID: 22027579
    [Abstract] [Full Text] [Related]

  • 8. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A, Menon MC.
    Curr Opin Investig Drugs; 2010 Sep 16; 11(9):1007-14. PubMed ID: 20730695
    [Abstract] [Full Text] [Related]

  • 9. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F, Blei AT, Blendis LM, Thuluvath PJ.
    Hepatology; 2003 Jan 16; 37(1):182-91. PubMed ID: 12500203
    [Abstract] [Full Text] [Related]

  • 10. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 11. Tolvaptan: any evidence of efficacy in SIADH?
    Prescrire Int; 2010 Oct 03; 19(109):197-200. PubMed ID: 21180368
    [Abstract] [Full Text] [Related]

  • 12. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N, Conivaptan Study Group.
    Am J Nephrol; 2007 Oct 03; 27(5):447-57. PubMed ID: 17664863
    [Abstract] [Full Text] [Related]

  • 13. Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan.
    Ferguson-Myrthil N.
    Cardiol Rev; 2010 Oct 03; 18(6):313-21. PubMed ID: 20926941
    [Abstract] [Full Text] [Related]

  • 14. Vaptans: a promising therapy in the management of advanced cirrhosis.
    Ginès P.
    J Hepatol; 2007 Jun 03; 46(6):1150-2. PubMed ID: 17445935
    [Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
    Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE.
    Biopharm Drug Dispos; 2013 Sep 03; 34(6):336-47. PubMed ID: 23794414
    [Abstract] [Full Text] [Related]

  • 16. Vasopressin-receptor antagonists.
    Hoorn EJ, Zietse R.
    Future Cardiol; 2010 Jul 03; 6(4):523-34. PubMed ID: 20608824
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan (Samsca) for hyponatremia.
    Med Lett Drugs Ther; 2009 Nov 30; 51(1326):95-6. PubMed ID: 20224525
    [No Abstract] [Full Text] [Related]

  • 18. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan.
    Friedman B, Cirulli J.
    J Crit Care; 2013 Apr 30; 28(2):219.e1-12. PubMed ID: 22884529
    [Abstract] [Full Text] [Related]

  • 19. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A.
    J Clin Endocrinol Metab; 2013 Apr 30; 98(4):1321-32. PubMed ID: 23401044
    [Abstract] [Full Text] [Related]

  • 20. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders.
    Josiassen RC, Curtis J, Filmyer DM, Audino B, Skuban N, Shaughnessy RA.
    Expert Opin Pharmacother; 2010 Mar 30; 11(4):637-48. PubMed ID: 20163274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.